Bronchoprovocation Study to Evaluate the Pharmacodynamics of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base

Inclusion Criteria: * Male and non-pregnant female subjects (18-65 years of age). * Stable mild asthmatics based on National Asthma Education and Prevention Program (NAEPP) guidelines. * FEV1 ≥ 80% of predicted. * Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline) PC20 ≤ 8 mg/mL. * Nonsmokers for at least six months prior to the study and a maximum smoking history of five pack-years (the equivalent of one pack per day for five years). * Written informed consent Exclusion Criteria: * Evidence of upper or lower respiratory tract infection (e.g., pneumonia, bronchitis, sinusitis) within six weeks prior to the study. * History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season. * History of cystic fibrosis, bronchiectasis or other respiratory diseases. * History of cardiovascular, renal, neurologic, liver or endocrine dysfunction, including ECG with evidence of ischemic heart disease. * Treatment in an emergency room or hospitalization for acute asthmatic symptoms or need for daily oral corticosteroids within past three months. * Known intolerance or hypersensitivity to any component of the albuterol MDI.